https://www.natap.org/2023/CROI/croi_02.htm
ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against...
viiv healthcareto presentlong actinghiv treatmentfirst
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-cabenuva-cabotegravir-rilpivirine-for-use-every-two-months-expanding-the-label-of-the-first-and-only-complete-long-acting-hiv-treatment/
ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two...
Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV.
us fda approvalviiv healthcareannouncescabenuvacabotegravir
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1698baf3-f895-4c42-a1b1-e9ee3f20da36&type=display
These highlights do not include all the information needed to use CABENUVA safely and effectively....
safely and effectivelythe informationhighlightsincludeneeded
https://www.jnj.com/media-center/press-releases/janssen-announces-u-s-fda-approval-of-cabenuva-rilpivirine-and-cabotegravir-the-first-long-acting-regimen-for-the-treatment-of-hiv
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First...
Jul 17, 2025 - CABENUVA offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression
u sfda approvalthe firstjanssenannounces